ArchiveJune 2013

EBV infection precedes to onset of MS: articles of Interest (16)

Is EBV the cause of MS? #MSBlog #MSResearch “Having been here from the beginning I incorrectly assume that all our readers would have gone back and read all our previous posts. How could they have there are now over 2600 to read. This paper has been covered before, but it is a very important paper. It shows that in EBV-negative people who go onto to develop MS, 100% of MSers EBV positive...

Gilenya affecting the processes driving progression?

Epub: Hemmati et al. Neurorestorative effect of FTY720 in a rat model of Alzheimer’s disease: Comparison with Memantine. Behav Brain Res. 2013 Jun.  Alzheimer’s disease (AD) as a neurodegenerative brain disorder is the most common cause of dementia. To date, there is no causative treatment for AD and there are few preventive treatments either. The sphingosine-1-phosphate receptor...

Remyelinating fish

Epub: Chung et al. Generation of demyelination models by targeted ablation of oligodendrocytes in the zebrafish CNS. Mol Cells. 2013 Jun 25. Demyelination is the pathological process by which myelin sheaths are lost from around axons, and is usually caused by a direct insult targeted at the oligodendrocytes in the vertebrate central nervous system (CNS). A demyelinated CNS is usually remyelinated...

Alemtuzumab and uncertainty: are you ready for it?

Uncertainty: how used to it are you? It may get worse before it gets better. #MSBlog #MSResearch “Some of you will be asking, after the euphoria of yesterday,how will Alemtuzumab play out in the field? This will depend on a risk benefit assessment; the risks of the drug, the benefits of the drug and the risk of having MS. The problem with risks and benefits is that at an individual level...

CCSVI June

Ferra H, Behrens G, Tumer Y, Riemenschneider M. Endovascular diagnosis and management of chronic cerebrospinal venous insufficiency: retrospective analysis of 30-day morbidity and mortality in 95 consecutive patients. AJR Am J Roentgenol. 2013;200(6):1358-64. doi: 10.2214/AJR.12.8938. OBJECTIVE. The purpose of this study is to report the 30-day morbidity and mortality associated with the...

Good news: alemtuzumab gets a first-line license in Europe

Today is a historic day for people with MS living in Europe. #MSBlog #MSResearch “Somebody asked for some good news. It doesn’t come much better than this.” Press release:  Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for approval of Aalemtuzumab...

Is MS a whole brain disease?

MS is a iceberg within and iceberg within an iceberg. #MSBlog #MSResearch “I am at a specialist MRI meeting in London. More thinking time; a precious resource. The meeting is focusing on MS as a whole brain disease. It is clear that MS is not only on iceberg, but an iceberg within an iceberg within an iceberg. What happens clinically is a fraction of what is seen on MRI and what is seen on...

Abnormal brain sodium in MS

Brain sodium is abnormal in MSers. #MSBlog #MSResearch “This is work done by our UCL partners (UCLP) at UCL and describes a new MRI technique that can quantify sodium. MSers have increased brain sodium content and it appears to correlates with disability. Exactly what this means is subject to debate and it may suggest a new therapeutic target. We are very active in this field and testing...

Translate

Categories

Recent Posts

Recent Comments

Archives